The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.

Szczegóły
Abstrakt

Tytuł:: The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Autorzy:: Giannakoulas N; Department of Hematology of University Hospital of Larisa, Faculty of Medicine, University of Thessaly, 41110 Larisa, Greece.
Ntanasis-Stathopoulos I; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Terpos E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Apr 24; Vol. 22 (9). Date of Electronic Publication: 2021 Apr 24.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:: Bone Marrow/*pathology
Multiple Myeloma/*pathology
Plasma Cells/*pathology
Tumor Microenvironment/*immunology
Animals ; Bone Marrow/immunology ; Humans ; Multiple Myeloma/immunology ; Plasma Cells/immunology
References:: Cancer Res. 2000 Apr 15;60(8):2178-89. (PMID: 10786682)
J Cancer Res Clin Oncol. 2014 Oct;140(10):1801-5. (PMID: 24906877)
Blood. 1996 Sep 15;88(6):2219-27. (PMID: 8822942)
Blood. 1989 May 15;73(7):1915-24. (PMID: 2713508)
Cells. 2020 Jan 24;9(2):. (PMID: 31991614)
Leukemia. 2008 Dec;22(12):2280-4. (PMID: 18528420)
J Int Med Res. 2012;40(2):556-64. (PMID: 22613416)
Blood Cancer J. 2020 Mar 2;10(3):25. (PMID: 32123158)
Haematologica. 2003 Feb;88(2):176-85. (PMID: 12604407)
Leukemia. 2003 Feb;17(2):427-36. (PMID: 12592343)
Hematol Oncol Clin North Am. 2007 Dec;21(6):1051-69, viii. (PMID: 17996588)
Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):57-62. (PMID: 31734019)
Blood Cancer J. 2016 May 27;6:e428. (PMID: 27232930)
Cell. 1997 Apr 18;89(2):309-19. (PMID: 9108485)
Leuk Lymphoma. 2013 Oct;54(10):2112-21. (PMID: 23432691)
Cancer Microenviron. 2011 Dec;4(3):325-37. (PMID: 21735169)
Br J Haematol. 1996 May;93(2):398-400. (PMID: 8639436)
Cancer Lett. 2016 Sep 28;380(1):114-21. (PMID: 27317873)
Exp Mol Med. 2013 Jan 10;45:e2. (PMID: 23306700)
Blood. 2014 Jun 12;123(24):3770-9. (PMID: 24782505)
Blood. 2004 Aug 1;104(3):607-18. (PMID: 15090448)
Leukemia. 2018 Jul;32(7):1500-1514. (PMID: 29535427)
Leukemia. 2009 Jan;23(1):10-24. (PMID: 18843284)
Blood. 2006 Dec 15;108(13):4194-7. (PMID: 16946299)
Semin Oncol. 2001 Dec;28(6):565-9. (PMID: 11740810)
Hum Immunol. 2009 Oct;70(10):854-7. (PMID: 19580833)
Haematologica. 2016 Dec;101(12):1451-1459. (PMID: 27903712)
Blood. 2009 May 28;113(22):5412-7. (PMID: 19179464)
Clin Cancer Res. 2012 Jan 15;18(2):342-9. (PMID: 22065077)
Blood. 2005 Jan 1;105(1):317-23. (PMID: 15339850)
Acta Haematol. 1997;97(4):191-5. (PMID: 9158660)
Semin Hematol. 1995 Jan;32(1):4-19. (PMID: 7878477)
J Clin Oncol. 2016 Aug 10;34(23):2698-704. (PMID: 27269947)
Hematol Oncol Clin North Am. 1992 Apr;6(2):273-84. (PMID: 1582974)
Cancer Res. 1995 Aug 15;55(16):3647-53. (PMID: 7543019)
Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e905-e909. (PMID: 32723621)
Am J Hematol. 2016 Jul;91(7):719-34. (PMID: 27291302)
J Immunol. 1997 Sep 1;159(5):2212-21. (PMID: 9278309)
Blood. 2017 Nov 30;130(22):2401-2409. (PMID: 29018077)
Leukemia. 2012 Jun;26(6):1391-401. (PMID: 22289923)
Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612. (PMID: 18070708)
Endocr Rev. 2013 Oct;34(5):658-90. (PMID: 23612223)
Clin Diagn Lab Immunol. 1995 Jan;2(1):44-52. (PMID: 7719912)
Blood. 2004 Aug 15;104(4):1120-6. (PMID: 15090460)
Haematologica. 2010 May;95(5):776-84. (PMID: 20015878)
Nature. 1997 Nov 13;390(6656):175-9. (PMID: 9367155)
Stem Cells Int. 2019 Jun 2;2019:6854080. (PMID: 31281380)
Int J Oncol. 1999 Dec;15(6):1205-12. (PMID: 10568829)
Clin Cancer Res. 2016 Jan 1;22(1):207-17. (PMID: 26341922)
Blood. 2013 Apr 11;121(15):2975-87. (PMID: 23321256)
Lancet Oncol. 2021 Mar;22(3):e119-e130. (PMID: 33545067)
Int J Cancer. 2019 Jul 15;145(2):559-568. (PMID: 30650184)
Blood. 2010 Dec 2;116(23):4815-28. (PMID: 20713966)
Clin Cancer Res. 2019 Jan 1;25(1):12-20. (PMID: 30093448)
Br J Haematol. 2007 Sep;138(5):563-79. (PMID: 17686051)
Eur J Cancer. 2006 Jul;42(11):1564-73. (PMID: 16765041)
Lancet Oncol. 2014 Nov;15(12):e538-48. (PMID: 25439696)
J Clin Invest. 2013 Apr;123(4):1542-55. (PMID: 23454749)
Carcinogenesis. 2018 Oct 8;39(10):1283-1291. (PMID: 30102336)
Br J Haematol. 2002 Apr;117(1):86-92. (PMID: 11918537)
Br J Haematol. 2003 Jun;121(6):842-8. (PMID: 12786794)
Cancer Biomark. 2019;24(2):195-201. (PMID: 30614800)
Blood. 1989 Feb;73(2):517-26. (PMID: 2783861)
Leukemia. 2013 Apr;27(4):780-91. (PMID: 23288300)
Cancer Immunol Immunother. 2015 Feb;64(2):213-24. (PMID: 25341809)
Cancer Res. 1989 Sep 1;49(17):4701-4. (PMID: 2667753)
Haematologica. 2005 Jun;90(6):810-7. (PMID: 15951294)
Haematologica. 2017 Jul;102(7):1273-1280. (PMID: 28360146)
Nat Rev Dis Primers. 2017 Jul 20;3:17046. (PMID: 28726797)
Lancet Haematol. 2019 Sep;6(9):e448-e458. (PMID: 31327689)
Blood. 2000 Apr 15;95(8):2630-6. (PMID: 10753844)
Haematologica. 2000 Aug;85(8):800-5. (PMID: 10942925)
Br J Haematol. 2002 Sep;118(3):817-20. (PMID: 12181051)
Radiol Med. 2021 Mar;126(3):445-452. (PMID: 32812173)
Cell. 1998 Apr 17;93(2):165-76. (PMID: 9568710)
Leukemia. 2015 Oct;29(10):2110-3. (PMID: 25778100)
Pathol Res Pract. 2010 Nov 15;206(11):753-9. (PMID: 20709463)
Expert Rev Hematol. 2019 Aug;12(8):651-663. (PMID: 31268745)
Blood. 2006 Sep 15;108(6):2020-8. (PMID: 16728703)
Exp Hematol. 2005 Feb;33(2):219-25. (PMID: 15676216)
Trends Cell Biol. 2015 Jun;25(6):364-72. (PMID: 25683921)
Oncogene. 2001 Sep 20;20(42):5991-6000. (PMID: 11593406)
Blood. 2014 Jul 24;124(4):555-66. (PMID: 24928860)
Am J Hematol. 2019 Apr;94(4):400-407. (PMID: 30592079)
Nat Rev Cancer. 2020 May;20(5):285-298. (PMID: 32112045)
Blood. 2010 Jul 1;115(26):5385-92. (PMID: 20395418)
Int J Hematol. 2002 Dec;76(5):460-4. (PMID: 12512841)
Cancer. 1998 May 15;82(10):1860-6. (PMID: 9587117)
Endocr Rev. 2012 Aug;33(4):547-94. (PMID: 22547160)
Blood. 2001 Oct 1;98(7):2229-38. (PMID: 11568011)
J Clin Immunol. 1992 Jul;12(4):239-47. (PMID: 1512298)
Hematol Oncol. 2017 Mar;35(1):51-57. (PMID: 26033514)
Br J Haematol. 2020 Nov 29;:. (PMID: 33249579)
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540-5. (PMID: 10097072)
Cancer Genet Cytogenet. 1998 Jul 15;104(2):133-8. (PMID: 9666807)
Blood. 2002 Jul 1;100(1):230-7. (PMID: 12070032)
Hematology Am Soc Hematol Educ Program. 2003;:248-78. (PMID: 14633785)
Endocrinology. 1994 Jan;134(1):213-21. (PMID: 8275936)
Eur J Immunol. 1993 Apr;23(4):820-4. (PMID: 8458373)
Cancer Res. 2000 Dec 1;60(23):6763-70. (PMID: 11118064)
Blood. 2003 Mar 15;101(6):2094-8. (PMID: 12424190)
Blood Rev. 2006 May;20(3):161-71. (PMID: 16364518)
Cancers (Basel). 2020 Jul 22;12(8):. (PMID: 32707884)
Hematol Oncol Clin North Am. 1997 Feb;11(1):27-42. (PMID: 9081202)
Blood. 1997 Aug 15;90(4):1649-55. (PMID: 9269785)
Cytometry A. 2020 May;97(5):496-503. (PMID: 31758756)
Nat Commun. 2018 Apr 27;9(1):1691. (PMID: 29703982)
BMC Cancer. 2010 May 13;10:198. (PMID: 20465808)
Br J Haematol. 1999 Dec;107(4):825-34. (PMID: 10606891)
Clin Cancer Res. 2013 Mar 1;19(5):985-94. (PMID: 23224402)
Am J Clin Pathol. 2012 Jan;137(1):93-100. (PMID: 22180482)
Br J Haematol. 1995 Sep;91(1):116-20. (PMID: 7577617)
Blood Cancer J. 2011 Jun;1(6):e27. (PMID: 22829171)
Pathol Oncol Res. 2015 Sep;21(4):929-34. (PMID: 25743259)
Leukemia. 2012 Nov;26(11):2424-8. (PMID: 22522789)
Med Hypotheses. 2005;65(5):1001-2. (PMID: 16002233)
Int J Cancer. 2012 Sep 15;131(6):1466-71. (PMID: 22052418)
Br J Haematol. 1994 May;87(1):68-74. (PMID: 7947257)
Blood. 2005 Jul 1;106(1):296-303. (PMID: 15755896)
Circ Res. 2008 Nov 21;103(11):1204-19. (PMID: 19028920)
Br J Haematol. 1998 May;101(2):296-301. (PMID: 9609525)
Blood. 2012 Feb 9;119(6):1468-78. (PMID: 22096244)
Haematologica. 2006 Aug;91(8):1033-40. (PMID: 16870555)
Bone. 2015 Jun;75:161-9. (PMID: 25725265)
J Exp Med. 1993 Sep 1;178(3):1023-31. (PMID: 8350044)
Leukemia. 1994 Aug;8(8):1285-9. (PMID: 8057663)
Haematologica. 2013 Oct;98(10):1586-92. (PMID: 23716545)
Blood Cancer J. 2018 May 11;8(5):42. (PMID: 29748532)
J Clin Oncol. 2015 Nov 20;33(33):3911-20. (PMID: 26282654)
Int J Hematol. 2016 Sep;104(3):300-9. (PMID: 27099225)
Leukemia. 2005 Mar;19(3):449-55. (PMID: 15674420)
Leukemia. 2009 Aug;23(8):1515-27. (PMID: 19357701)
Blood. 2006 May 15;107(10):3940-9. (PMID: 16410445)
Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):67-79. (PMID: 16569345)
Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):29-33. (PMID: 18234635)
Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S83-93. (PMID: 23692463)
Bone. 2011 Jan;48(1):135-40. (PMID: 20601285)
World J Stem Cells. 2014 Jul 26;6(3):322-43. (PMID: 25126382)
PLoS One. 2012;7(11):e49446. (PMID: 23152910)
Blood. 2000 Sep 1;96(5):1953-60. (PMID: 10961900)
Cancer Invest. 1993;11(6):751-8. (PMID: 8221208)
Cancer Res. 2009 Feb 1;69(3):1009-15. (PMID: 19155309)
Leukemia. 2013 Feb;27(2):464-72. (PMID: 22828443)
J Biol Chem. 1990 Oct 5;265(28):17238-45. (PMID: 1698773)
Leuk Res. 2017 Sep;60:82-88. (PMID: 28759800)
Histol Histopathol. 2005 Oct;20(4):1227-50. (PMID: 16136504)
J Investig Med. 2020 Jan;68(1):45-51. (PMID: 31784427)
Stem Cell Res Ther. 2015 Jul 01;6:127. (PMID: 26129847)
Blood Cancer J. 2018 Jan 12;8(1):7. (PMID: 29330358)
Adv Immunol. 1993;54:1-78. (PMID: 8379461)
Science. 1986 Apr 4;232(4746):61-5. (PMID: 2420009)
Nat Immunol. 2014 Mar;15(3):275-82. (PMID: 24441790)
Blood. 2003 Jul 15;102(2):638-45. (PMID: 12649156)
Clin Cancer Res. 2006 Dec 1;12(23):6973-7. (PMID: 17145816)
Cell Rep. 2017 Apr 4;19(1):218-224. (PMID: 28380360)
Cytokine. 2001 Nov 7;16(3):79-86. (PMID: 11741345)
Blood. 2019 Jun 6;133(23):2484-2494. (PMID: 31010848)
Br J Haematol. 2012 Aug;158(3):336-46. (PMID: 22583117)
Blood. 1999 May 1;93(9):3064-73. (PMID: 10216103)
Eur J Immunol. 1997 Sep;27(9):2245-52. (PMID: 9341766)
Blood. 2019 Apr 4;133(14):1534-1539. (PMID: 30760454)
Blood. 2008 Jul 1;112(1):159-68. (PMID: 18436739)
Blood. 2004 Oct 15;104(8):2484-91. (PMID: 15187021)
Clin Cancer Res. 2002 Jul;8(7):2210-6. (PMID: 12114422)
Nat Rev Rheumatol. 2016 Mar;12(3):154-68. (PMID: 26607387)
Leukemia. 2009 Dec;23(12):2210-21. (PMID: 19798094)
J Clin Invest. 2004 Nov;114(9):1317-25. (PMID: 15520864)
Blood. 2014 Apr 3;123(14):2204-8. (PMID: 24425802)
Cancer. 1992 Mar 15;69(6):1373-6. (PMID: 1540875)
Br J Cancer. 2016 Feb 16;114(4):463-8. (PMID: 26882069)
Blood. 2019 Feb 14;133(7):660-675. (PMID: 30587529)
Lancet Haematol. 2019 Sep;6(9):e459-e469. (PMID: 31327687)
J Clin Oncol. 2015 Sep 10;33(26):2863-9. (PMID: 26240224)
Int J Biol Markers. 2004 Jan-Mar;19(1):52-7. (PMID: 15077927)
Mol Cancer. 2010 Jul 06;9:176. (PMID: 20604947)
Leuk Lymphoma. 2005 Dec;46(12):1699-707. (PMID: 16263571)
Blood. 2010 Nov 4;116(18):3554-63. (PMID: 20664052)
J Immunol. 2013 Jun 1;190(11):5882-93. (PMID: 23630344)
Blood. 2001 Feb 1;97(3):729-36. (PMID: 11157491)
J Oncol. 2013;2013:183602. (PMID: 23431298)
Carcinogenesis. 2017 Jul 1;38(7):708-716. (PMID: 28838065)
J Immunol. 2013 Apr 1;190(7):3815-23. (PMID: 23460744)
J Cell Physiol. 2001 Oct;189(1):54-63. (PMID: 11573204)
AJR Am J Roentgenol. 2021 Mar;216(3):742-751. (PMID: 33439048)
Blood. 2006 Sep 1;108(5):1661-7. (PMID: 16684957)
Oncotarget. 2015 Oct 27;6(33):34329-41. (PMID: 26455377)
Nature. 1986 Jan 30-Feb 5;319(6052):415-8. (PMID: 3484805)
Leuk Lymphoma. 2010 May;51(5):920-7. (PMID: 20367137)
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7841-5. (PMID: 11427725)
Blood. 1998 Jan 1;91(1):3-21. (PMID: 9414264)
Oncogene. 2002 Feb 21;21(9):1391-400. (PMID: 11857082)
Contributed Indexing:: Keywords: bone disease; bone marrow; cytokines; immune cells; mesenchymal stem cells; microenvironment; multiple myeloma; osteoblasts; osteoclasts; plasma cells
Entry Date(s):: Date Created: 20210430 Date Completed: 20210514 Latest Revision: 20210518
Update Code:: 20240104
PubMed Central ID:: PMC8123209
DOI:: 10.3390/ijms22094462
PMID:: 33923357
: Czasopismo naukowe

Pełny tekst

The development and effectiveness of novel therapies in multiple myeloma have been established in large clinical trials. However, multiple myeloma remains an incurable malignancy despite significant therapeutic advances. Accumulating data have elucidated our understanding of the genetic background of the malignant plasma cells along with the role of the bone marrow microenvironment. Currently, the interaction among myeloma cells and the components of the microenvironment are considered crucial in multiple myeloma pathogenesis. Adhesion molecules, cytokines and the extracellular matrix play a critical role in the interplay among genetically transformed clonal plasma cells and stromal cells, leading to the proliferation, progression and survival of myeloma cells. In this review, we provide an overview of the multifaceted role of the bone marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma.

Informacja